The significance of Dr Paul in the ACTC drug commercialization equation.
To fully understand the significance and the importance of Dr. Paul Wotton's addition to the management team of ACTC, especially at this time, is to first look at and understand the various ophthalmic solutions market. This market is huge and cater to all ocular maladies that spans the globe, from the Americas to the EMEA and APAC regions.
This market is expected to grow at an impressive steady CAGR rate in the very near future.
Key Vendors in this market include:
- Allergan Inc.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
Other Prominent Vendors in this market, include
- Acadia Pharmaceuticals Inc.
- AC Immune SA
- Acorn Biomedical Inc.
- Advanced Cell Technology Inc.
- Aerie Pharmaceuticals Inc., to mention a few.
Now what is the intrigue? Key vendors in this market are Pharma titans like Merck and Pfizer. Why are these two stand outs? Start with Pfizer. Recall Pfizer has a collaborative cell line deal with the same biotech firm in Europe that ACTC have ties with. Then Dr. Wotton gets hired as its new CEO, by ACTC to lead the company in their quest to bring their flagship therapy to market. Interestingly, Dr. Wotton has had strong ties with Merck...coincidence?
Connect the dots, and ACTC seem to be poised and on track to make the long wait interesting and rewarding. Do ya DD and be a smart trader/investor to make ACTC worth your while. Only use monies you can afford to lose.....
Being able to raise $30 MILLION makes ACTC's commercialization equation more tantalizing and interesting, imho. No investor will sink $30 Mill into a vehicle that's going nowhere fast, unless of course the vehicle is on a path to somewhere, under the able commandership of a Dr. Wotton. I am now confident of my expectations of ACTC, at least after RS.